NAMS
NewAmsterdam Pharma Company N.V.
NASDAQ · Healthcare · Biotechnology · NL
$25.40
−1.74%Aug 14, 2026, 00:00 UTC
NewAmsterdam Pharma Co N.V. appointed Robert W. Gunning as principal accounting officer, Vice President and Controller, effective August 10, 2026, succeeding Louise Kooij who will depart on August 31, 2026.
Aug 5, 2026, 11:00 UTC
NewAmsterdam Pharma announced that the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe.
Source:Aug 5, 2026, 00:00 UTC
NewAmsterdam Pharma reported Q2 2026 revenue of $3.7 million, down 80.6% year-over-year, and a net loss of $64.1 million.
Source:Jul 26, 2026, 17:59 UTC
NewAmsterdam Pharma and Menarini Group received a positive CHMP opinion recommending marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (fixed-dose combination of obicetrapib and ezetimibe).
Source:Jul 24, 2026, 12:00 UTC
The CHMP of the European Medicines Agency adopted a positive opinion recommending marketing authorization for NewAmsterdam Pharma's Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in Europe.
Jun 3, 2026, 00:00 UTC
NewAmsterdam Pharma Co N.V. elected John W. Smither and Janneke van der Kamp as non-executive directors, effective June 2, 2026.